Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Korea Lays Essential Drug Plans Amid Ongoing Supply Concerns

Executive Summary

South Korea unveils measures to stabilize supply of essential drugs – including a list of the drugs to monitor, stockpile and manage – to deal with public health crises in time and guarantee treatment opportunities for the nation.

You may also be interested in...

State-Owned Pharma Group On Horizon As Korea Eyes Secure Supplies

South Korea is mulling setting up a state-owned pharma firm as lawmakers, government officials and experts reach consensus during a recent public hearing that official intervention and control could help stabilize drug supplies and promptly deal with public health and other emergency situations.

Korea Seeks New Law To Support Orphan Drugs, Ease Supply Disruptions

Amid continued disruptions in medicine supplies and growing need to develop orphan drugs, South Korea’s government plans to submit a bill to parliament that will enable it to designate "innovative medicines" for the treatment of fatal or incurable diseases, help speed up the development and approval of innovative drugs, as well as ease supply disruptions.

Does South Korea Need A State-Owned Pharma To Stabilize Supply?

South Korea repeatedly faced drug supply disruptions when dealing with the outbreak of bird flu and new influenza, and when pharma firms refused to produce inexpensive but essential medicines, or drugs for rare diseases, due to low profitability. A local research paper now says the country may need a state-run pharma to ensure stable future supplies of essential medicines.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts